Go Pro
OTCMKTS:SHTDY

Sinopharm Group (SHTDY) Stock Price, News & Analysis

Sinopharm Group logo
$10.61 -0.03 (-0.24%)
As of 02:31 PM Eastern

About Sinopharm Group Stock (OTCMKTS:SHTDY)

Advanced

Key Stats

Today's Range
$10.59
$10.65
50-Day Range
$10.05
$11.37
52-Week Range
$10.00
$14.87
Volume
39,507 shs
Average Volume
87,443 shs
Market Capitalization
N/A
P/E Ratio
2.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sinopharm Group Co., Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co., Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.

In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions. The retail segment operates both company-owned and franchised pharmacies, providing consumers with access to general medicines, health supplements, diagnostic testing services and basic medical consultations. The group also engages in contract manufacturing of bulk pharmaceutical ingredients and finished dosage formulations, and maintains strategic partnerships for the research, development and commercialization of vaccines and biologics.

Founded in 1998 and listed on the Shanghai Stock Exchange in December 2009 as one of the first A-share pharmaceutical companies, Sinopharm has continually expanded its footprint beyond China, establishing subsidiaries and joint ventures in Asia, Europe, the Middle East and Africa. The company is governed by a board of directors and senior management team tasked with navigating regulatory landscapes and advancing innovation in healthcare delivery. Through ongoing investment in digital supply chain technologies and strategic alliances, Sinopharm aims to enhance accessibility and affordability of medical products for a rapidly aging population.

AI Generated. May Contain Errors.

Receive SHTDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SHTDY Stock News Headlines

Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.tc pixel
Sinopharm Group Reports Q1 2025 Financial Results
See More Headlines

SHTDY Stock Analysis - Frequently Asked Questions

Sinopharm Group's stock was trading at $12.40 at the start of the year. Since then, SHTDY shares have decreased by 14.4% and is now trading at $10.62.

Shares of SHTDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/12/2026
Next Earnings (Estimated)
8/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Providers & Services
Sub-Industry
N/A
Current Symbol
OTCMKTS:SHTDY
CIK
1556605
Fax
N/A
Employees
115,959
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
2.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (OTCMKTS:SHTDY) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners